Veracyte receives Medicare coverage for bladder cancer monitoring test
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
May 15, 2026 9:00 AM EDTMarks the first Medicare coverage decision for Veracytes whole-genome sequencing-based TrueMRD platform and launch of the first test
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its TrueMRD Monitoring Test has received coverage from the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Services Program (MolDX) for patients with muscle-invasive bladder cancer (MIBC). The TrueMRD Test is covered for recurrence monitoring following definitive treatment with curative intent in patients with MIBC. It will be available for clinicians to... More
